Loading…
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era
We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell tran...
Saved in:
| Published in: | Cancer science 2015-02, Vol.106 (2), p.179-185 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3 |
| container_end_page | 185 |
| container_issue | 2 |
| container_start_page | 179 |
| container_title | Cancer science |
| container_volume | 106 |
| creator | Takamatsu, Hiroyuki Honda, Sumihisa Miyamoto, Toshihiro Yokoyama, Kenji Hagiwara, Shotaro Ito, Toshiro Tomita, Naoto Iida, Shinsuke Iwasaki, Toshihiro Sakamaki, Hisashi Suzuki, Ritsuro Sunami, Kazutaka |
| description | We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre‐novel agent era (1995–2006) and novel agent era (2008–2011). The combined percentage of pre‐ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre‐novel agent era (164 of 527, 31%; P |
| doi_str_mv | 10.1111/cas.12594 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4399028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1658417732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3</originalsourceid><addsrcrecordid>eNp1kktv1DAQgCMEoqVw4A8gS1zgkK6TOHF8QapWvKRKHICzNUkmWVd-BD9a7X_iR-LdLRUg4Ystz6dvZuwpipcVvazy2owQLqu6FexRcV41TJSc0u7x8cxLQZv6rHgWwg2lTccEe1qc1W3bUFo358XP7Q7souxCokc7BaIsWb1brAtRjWSGMTofyOw8WSEqtDGQOxV3xCQd1aqRmD1qZ4DAHNETSNFpt7gUSIhoyIhaZzXYsGqwMSucJVPyx4w7JMqYZJ1xU9KQM5HJp2WTC4gIwZkctzs1qEMEPTwvnsygA7643y-K7x_ef9t-Kq-_fPy8vboux45xVo5csLGd2MxBdLyhHevZVIm6R5xpK1o203oA3oqpEaKqhoH3AwcUwBBGzLcXxbuTd02DwWnMXXvQcvXKgN9LB0r-HbFqJxd3K1kW0rrPgjf3Au9-JAxRGhUOTwEW89PIqmt7VnHe1Bl9_Q9645K3uT1Z173our7pmky9PVGjdyF4nB-Kqag8zIDMMyCPM5DZV39W_0D-_vQMbE7AndK4_79Jbq--npS_ANDEwco</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289668363</pqid></control><display><type>article</type><title>Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Wiley_OA刊</source><creator>Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka</creator><creatorcontrib>Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka</creatorcontrib><description>We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre‐novel agent era (1995–2006) and novel agent era (2008–2011). The combined percentage of pre‐ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre‐novel agent era (164 of 527, 31%; P < 0.0001). The 2‐year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre‐novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre‐novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era.
We evaluated the clinical significance of the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma who underwent upfront single autologous stem cell transplantation (ASCT). The factors that were independently associated with superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (PR) (P < 0.001), and ASCT during the novel agent era (P = 0.017). No significant differences in OS were found between the ISS I and II (P = 0.107) during the novel agent era.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.12594</identifier><identifier>PMID: 25530023</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autografts ; Autologous stem cell transplantation ; Blood ; Chemotherapy ; Female ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Immunologic Factors - administration & dosage ; immunomodulator drugs ; International Staging System ; Male ; Medical prognosis ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - immunology ; Multiple Myeloma - metabolism ; Original ; Patients ; Prognosis ; Proteasome inhibitors ; Proteasome Inhibitors - administration & dosage ; Retrospective Studies ; Stem cell transplantation ; Stem cells ; Survival Rate ; Transplantation, Autologous - methods ; Transplants & implants ; Urine ; Young Adult</subject><ispartof>Cancer science, 2015-02, Vol.106 (2), p.179-185</ispartof><rights>2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</rights><rights>2015. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3</citedby><cites>FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2289668363/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2289668363?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25530023$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takamatsu, Hiroyuki</creatorcontrib><creatorcontrib>Honda, Sumihisa</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Yokoyama, Kenji</creatorcontrib><creatorcontrib>Hagiwara, Shotaro</creatorcontrib><creatorcontrib>Ito, Toshiro</creatorcontrib><creatorcontrib>Tomita, Naoto</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><creatorcontrib>Iwasaki, Toshihiro</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Suzuki, Ritsuro</creatorcontrib><creatorcontrib>Sunami, Kazutaka</creatorcontrib><title>Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre‐novel agent era (1995–2006) and novel agent era (2008–2011). The combined percentage of pre‐ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre‐novel agent era (164 of 527, 31%; P < 0.0001). The 2‐year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre‐novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre‐novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era.
We evaluated the clinical significance of the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma who underwent upfront single autologous stem cell transplantation (ASCT). The factors that were independently associated with superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (PR) (P < 0.001), and ASCT during the novel agent era (P = 0.017). No significant differences in OS were found between the ISS I and II (P = 0.107) during the novel agent era.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autografts</subject><subject>Autologous stem cell transplantation</subject><subject>Blood</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Immunologic Factors - administration & dosage</subject><subject>immunomodulator drugs</subject><subject>International Staging System</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - immunology</subject><subject>Multiple Myeloma - metabolism</subject><subject>Original</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proteasome inhibitors</subject><subject>Proteasome Inhibitors - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous - methods</subject><subject>Transplants & implants</subject><subject>Urine</subject><subject>Young Adult</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kktv1DAQgCMEoqVw4A8gS1zgkK6TOHF8QapWvKRKHICzNUkmWVd-BD9a7X_iR-LdLRUg4Ystz6dvZuwpipcVvazy2owQLqu6FexRcV41TJSc0u7x8cxLQZv6rHgWwg2lTccEe1qc1W3bUFo358XP7Q7souxCokc7BaIsWb1brAtRjWSGMTofyOw8WSEqtDGQOxV3xCQd1aqRmD1qZ4DAHNETSNFpt7gUSIhoyIhaZzXYsGqwMSucJVPyx4w7JMqYZJ1xU9KQM5HJp2WTC4gIwZkctzs1qEMEPTwvnsygA7643y-K7x_ef9t-Kq-_fPy8vboux45xVo5csLGd2MxBdLyhHevZVIm6R5xpK1o203oA3oqpEaKqhoH3AwcUwBBGzLcXxbuTd02DwWnMXXvQcvXKgN9LB0r-HbFqJxd3K1kW0rrPgjf3Au9-JAxRGhUOTwEW89PIqmt7VnHe1Bl9_Q9645K3uT1Z173our7pmky9PVGjdyF4nB-Kqag8zIDMMyCPM5DZV39W_0D-_vQMbE7AndK4_79Jbq--npS_ANDEwco</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Takamatsu, Hiroyuki</creator><creator>Honda, Sumihisa</creator><creator>Miyamoto, Toshihiro</creator><creator>Yokoyama, Kenji</creator><creator>Hagiwara, Shotaro</creator><creator>Ito, Toshiro</creator><creator>Tomita, Naoto</creator><creator>Iida, Shinsuke</creator><creator>Iwasaki, Toshihiro</creator><creator>Sakamaki, Hisashi</creator><creator>Suzuki, Ritsuro</creator><creator>Sunami, Kazutaka</creator><general>John Wiley & Sons, Inc</general><general>BlackWell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201502</creationdate><title>Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era</title><author>Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autografts</topic><topic>Autologous stem cell transplantation</topic><topic>Blood</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Immunologic Factors - administration & dosage</topic><topic>immunomodulator drugs</topic><topic>International Staging System</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - immunology</topic><topic>Multiple Myeloma - metabolism</topic><topic>Original</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proteasome inhibitors</topic><topic>Proteasome Inhibitors - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous - methods</topic><topic>Transplants & implants</topic><topic>Urine</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takamatsu, Hiroyuki</creatorcontrib><creatorcontrib>Honda, Sumihisa</creatorcontrib><creatorcontrib>Miyamoto, Toshihiro</creatorcontrib><creatorcontrib>Yokoyama, Kenji</creatorcontrib><creatorcontrib>Hagiwara, Shotaro</creatorcontrib><creatorcontrib>Ito, Toshiro</creatorcontrib><creatorcontrib>Tomita, Naoto</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><creatorcontrib>Iwasaki, Toshihiro</creatorcontrib><creatorcontrib>Sakamaki, Hisashi</creatorcontrib><creatorcontrib>Suzuki, Ritsuro</creatorcontrib><creatorcontrib>Sunami, Kazutaka</creatorcontrib><collection>Wiley_OA刊</collection><collection>Wiley Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takamatsu, Hiroyuki</au><au>Honda, Sumihisa</au><au>Miyamoto, Toshihiro</au><au>Yokoyama, Kenji</au><au>Hagiwara, Shotaro</au><au>Ito, Toshiro</au><au>Tomita, Naoto</au><au>Iida, Shinsuke</au><au>Iwasaki, Toshihiro</au><au>Sakamaki, Hisashi</au><au>Suzuki, Ritsuro</au><au>Sunami, Kazutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2015-02</date><risdate>2015</risdate><volume>106</volume><issue>2</issue><spage>179</spage><epage>185</epage><pages>179-185</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre‐novel agent era (1995–2006) and novel agent era (2008–2011). The combined percentage of pre‐ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre‐novel agent era (164 of 527, 31%; P < 0.0001). The 2‐year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre‐novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre‐novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era.
We evaluated the clinical significance of the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma who underwent upfront single autologous stem cell transplantation (ASCT). The factors that were independently associated with superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre‐ASCT response at least partial response (PR) (P < 0.001), and ASCT during the novel agent era (P = 0.017). No significant differences in OS were found between the ISS I and II (P = 0.107) during the novel agent era.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>25530023</pmid><doi>10.1111/cas.12594</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2015-02, Vol.106 (2), p.179-185 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4399028 |
| source | Open Access: PubMed Central; Publicly Available Content Database; Wiley_OA刊 |
| subjects | Adjuvants, Immunologic - therapeutic use Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Autologous stem cell transplantation Blood Chemotherapy Female Hematopoietic Stem Cell Transplantation - methods Humans Immunologic Factors - administration & dosage immunomodulator drugs International Staging System Male Medical prognosis Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - immunology Multiple Myeloma - metabolism Original Patients Prognosis Proteasome inhibitors Proteasome Inhibitors - administration & dosage Retrospective Studies Stem cell transplantation Stem cells Survival Rate Transplantation, Autologous - methods Transplants & implants Urine Young Adult |
| title | Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A29%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changing%20trends%20in%20prognostic%20factors%20for%20patients%20with%20multiple%20myeloma%20after%20autologous%20stem%20cell%20transplantation%20during%20the%20immunomodulator%20drug/proteasome%20inhibitor%20era&rft.jtitle=Cancer%20science&rft.au=Takamatsu,%20Hiroyuki&rft.date=2015-02&rft.volume=106&rft.issue=2&rft.spage=179&rft.epage=185&rft.pages=179-185&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.12594&rft_dat=%3Cproquest_pubme%3E1658417732%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c6474-c794c5d4f7a967306484d1928eef05954f02ba759d39911bb78b7ae9a4eace9d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2289668363&rft_id=info:pmid/25530023&rfr_iscdi=true |